NRAS and non-small cell lung carcinoma: In recent years, KRASG12C inhibitors (AMG510) have been developed and approved for KRASG12C-mutated non-small cell lung cancer (NSCLC) patients [4]; however, there is no approved drug for NRAS-mutant tumors [5].